Introduction
============

Inhaled anticholinergic medications, including short-acting ipratropium bromide (ipratropium) and long-acting tiotropium bromide (tiotropium), are mainstays for the treatment of symptoms of chronic obstructive pulmonary disease (COPD). The safety profiles of these drugs comprise systemic anticholinergic events, including dry mouth, constipation, urinary retention and cardiac effects, including palpitations, tachycardia and supraventricular tachycardia (SVT).[@b1; @b2; @b3; @b4; @b5] There has been concern that anticholinergic drugs could induce ischaemia, possibly secondary to tachyarrhythmias,[@b4] [@b5] and could pose a risk to patients with cardiovascular complications.[@b6] Among patients with congestive heart failure, SVT is a risk factor for stroke, as well as cardiovascular hospitalisation and death.[@b7] Furthermore, among patients with sinus node dysfunction, asymptomatic atrial tachyarrhythmias increase the risk of stroke and death.[@b8]

We conducted this epidemiologic study to examine the possible association between tiotropium (HandiHaler® powder formulation) and risk of stroke and other cardiovascular adverse events, including angina and myocardial infarction (MI).

Methods
=======

Treatment guidelines for COPD consider long-acting bronchodilators as a class and make no distinction between anticholinergic drugs and long-acting β agonists (LABAs), resulting in clinical equipoise.[@b9] Therefore, new users of tiotropium were compared with new users of LABAs.[@b10] [@b11] Both long-acting bronchodilators are indicated for treating symptoms of COPD; LABAs are also indicated for the treatment of asthma.

The source population included patients in the UK enrolled with a general practitioner who contributes to The Health Improvement Network (THIN) primary care database. The THIN database includes deidentified patient records containing demographic data, medical history, prescribed medications, diagnostic tests, laboratory results, specialist referrals and some lifestyle characteristics.[@b12] The database is derived from the same software as the General Practice Research Database and has been validated for COPD, as well as stroke and MI, and is widely used in epidemiologic research.[@b12; @b13; @b14]

Patients had to have at least one prescription for tiotropium (HandiHaler formulation) or LABA (salmeterol or formoterol) from November 2002 (the earliest use of tiotropium) until January 2007. Because tiotropium is available only in a single-ingredient preparation, whereas LABAs are also available in combination with inhaled corticosteroids, the LABA group was restricted to patients prescribed single-ingredient LABAs. Patients had to have at least two years of baseline data with no use of a long-acting inhaler prior to their first or "index" prescription for tiotropium or LABA. To reduce confounding by indication, patients who had a recorded diagnosis of asthma as their only respiratory diagnosis were excluded, as were patients less than 40 years old.

Study end points included various cardiovascular adverse events (aneurysm, atrial fibrillation, cardiac arrest, coronary artery disease, angina, MI, heart failure, hypertension, stroke, syncope, tachycardia and ventricular tachycardia), respiratory adverse events (COPD exacerbation, asthma exacerbation and pneumonia) and other adverse events of interest (constipation, dry mouth, dysphagia, paralytic ileus/bowel obstruction, renal failure, tremor, urinary retention). Information on causes of death was unavailable, but we were able to examine all-cause mortality. Most end points were defined using medical codes from the Read Clinical Classification Version 2, May 2006. Mortality was identified from a combination of READ codes, registration status, additional health data codes and enrolment dates.

Covariates were selected for inclusion in the analysis based on clinical importance and included respiratory diagnosis (COPD/no asthma, COPD and asthma, other (ie, asthma or COPD not recorded)), age, sex, calendar year of drug start, smoking, body mass index, number of hospitalisations in the year prior to cohort entry, number of general practitioner visits in the year prior to cohort entry, cardiac comorbidities (ischaemic heart disease, arrhythmias, hypertension), respiratory medications (number of prescriptions for short-acting anticholinergics, short-acting β-agonists, inhaled corticosteroids, oral corticosteroids and use of theophyllines and cromoglycates), cardiac medications (prescriptions for anti-arrhythmics, anticoagulants, anti-hypertensives, ACE inhibitors, diuretics, inotropics, lipid regulators, β-blockers, nitrates), other medications (gastrointestinal, vascular, central nervous system, infectious disease, endocrine, gynaecologic/urinary tract, malignancy, nutrition/blood disorders), oxygen use, lung cancer diagnosis prior to index and history of diabetes.

People were classified as exposed to study medication for the duration of prescribed therapy plus 30 days. For the analysis of each end point, patients were followed from the date of their first eligible prescription until the earliest of the following: date of treatment end, date of study end point, date of transfer to a new practice, death or January 2007. Each end point was analysed separately, so patients who experienced more than one end point under study were included in analyses of each event.

Incidence rates of the study end points were calculated as the number of patients experiencing an event divided by the person-years at risk. Incidence rate ratios were calculated as the incidence rate in the tiotropium group divided by the incidence rate in the LABA group. Precision of effect estimates was evaluated from the width of the 95% CIs.[@b15]

Some end points were rare relative to the number of factors that needed to be controlled, so propensity scores (derived from logistic regression models) were used to enhance efficiency of analytic control of confounding.[@b16] The propensity score is the estimated chance of a patient receiving tiotropium compared with LABA, given a patient\'s observed set of covariates (prognostic variables). In constructing the logistic models used to calculate the propensity scores, all available variables described above were entered into the model.

Multivariate analysis was performed using Cox\' proportional hazard model with adjustment for indicators of propensity score quintile to estimate adjusted HRs and corresponding 95% CIs.[@b17] The assumption of proportionality of the hazards was tested by including time-dependent covariates in the Cox model.[@b17] We also computed effect estimates using Poisson regression. Effect estimates are presented for end points where the event was detected in at least five patients in each treatment group.

To identify a study population of more compliant long-term users, we also conducted analyses restricted to patients on treatment for greater than 6 months. In addition, analyses were stratified by respiratory diagnostic status (COPD and asthma, COPD without asthma, other), use of oral corticosteroids and history of coronary artery disease.

All analyses were performed using STATA V.7.0 and SAS V.9.1. This study received ethical approval from the UK Department of Health Multicentre Research Ethics Committee.

Results
=======

The study population included 4767 tiotropium patients and 6073 LABA patients who contributed 2775 person-years of exposure to tiotropium and 2303 person-years of exposure to a single-ingredient LABA ([table 1](#tbl1){ref-type="table"}). Mean duration of exposure was 212 days for tiotropium patients and 139 days for LABA patients. Ninety-five per cent of LABA prescriptions were for salmeterol. Though a similar proportion of tiotropium and LABA patients switched or added a different long-acting bronchodilator thereby terminating study participation, a lower proportion of tiotropium patients than LABA patients discontinued use of a long-acting bronchodilator prior to the administrative end of the study (58% compared with 73%). The proportion of current smokers was slightly higher in tiotropium users than in LABA users (37% compared with 30%). Other covariates were generally balanced between treatment groups.

###### 

Demographic characteristics of the study population

                    Tiotropium, n=4767   LABA[\*](#table-fn1){ref-type="table-fn"}, n=6073          
  ----------------- -------------------- --------------------------------------------------- ------ ----
  Age group                                                                                         
   40--49           149                  3                                                   362    6
   50--59           641                  13                                                  943    16
   60--69           1391                 29                                                  1730   28
   70--79           1759                 37                                                  1991   33
   80--89           769                  16                                                  976    16
   90+              58                   1                                                   71     1
  Sex                                                                                               
   Male             2707                 57                                                  3073   51
   Female           2060                 43                                                  3000   49
  Body mass index                                                                                   
   Low              634                  13                                                  613    10
   Normal           1500                 31                                                  1799   30
   Overweight       1413                 30                                                  1895   31
   Obese            1012                 21                                                  1467   24
   Missing          208                  4                                                   299    5
  Smoking                                                                                           
   Never            562                  12                                                  1077   18
   Current          1765                 37                                                  1812   30
   Former           2343                 49                                                  2960   49
   Missing          97                   2                                                   224    4

Long-acting β-agonist single-ingredient formulations.

Characteristics of medical history prior to study entry are shown in [table 2](#tbl2){ref-type="table"}. A high proportion of patients in both groups had spirometry testing (89% of tiotropium patients and 84% of LABA patients) and a diagnosis of COPD (89% of tiotropium patients and 88% of LABA patients). More LABA patients than tiotropium patients also had an asthma codiagnosis (42% vs 63%).

###### 

Medical history of the study population by long-acting bronchodilator

  --------------------------------------------------------------------------- ------ ---- ------ ----
  Prior respiratory diagnosis                                                                    
   COPD and asthma                                                            1807   38   3366   55
   COPD only                                                                  2450   51   1960   32
   Other                                                                      510    11   747    12
  Use of respiratory medications[†](#table-fn3){ref-type="table-fn"}                             
   Short-acting anticholinergics                                              1948   41   2372   39
   Short-acting β-agonists                                                    3372   71   5053   83
   Inhaled corticosteroids                                                    1904   40   3610   59
   Oral corticosteroids                                                       1396   29   2227   37
   Theophyllines                                                              238    5    361    6
   Cromoglycates                                                              48     1    67     1
  Use of oxygen                                                               187    4    175    3
  Use of cardiac medications[†](#table-fn3){ref-type="table-fn"}                                 
   Anti-arrhythmics                                                           219    5    312    5
   Anti-coagulants                                                            1834   38   2069   34
   Anti-hypertensives                                                         2424   51   2913   48
   ACE inhibitors                                                             1162   24   1380   23
   Diuretics                                                                  1912   40   2336   38
   Inotropics                                                                 254    5    286    5
   Lipid regulators                                                           1413   30   1509   25
   β-Blockers                                                                 613    13   537    9
   Nitrates                                                                   704    15   843    14
  History of ischaemic heart disease                                          233    5    319    5
  History of arrhythmia                                                       139    3    165    3
  History of hypertension                                                     1785   37   2202   36
  History of diabetes                                                         456    10   591    10
  Use of spirometry (at least once)                                           4225   89   5093   84
  Number of general practitioner visits[†](#table-fn3){ref-type="table-fn"}                      
   0                                                                          357    6    288    7
   1--5                                                                       2167   45   2577   42
   6--10                                                                      1415   30   1902   31
   11+                                                                        897    19   1237   20
  Number of hospital admissions[†](#table-fn3){ref-type="table-fn"}                              
   0                                                                          4143   87   5097   84
   1--2                                                                       502    11   791    13
   3+                                                                         122    3    185    3
  --------------------------------------------------------------------------- ------ ---- ------ ----

Single-ingredient formulations.

365 days prior to index date.

COPD, chronic obstructive pulmonary disease; N, number; LABA, long-acting β-agonists.

Results from Cox models and Poisson models were similar, so estimates from Cox models are presented ([table 3](#tbl3){ref-type="table"}). There were small increases in the tiotropium group in the rates of angina (HR=1.38, 95% CI 0.88 to 2.16), MI (HR=1.26, 95% CI 0.72 to 2.21) and stroke (HR=1.49, 95% CI 0.91 to 2.45). There were similar rates between treatment groups of aneurysm (HR=0.96, 95% CI 0.44 to 2.05), atrial fibrillation or flutter (HR=0.99, 95% CI 0.71 to 1.38), coronary artery disease (HR=1.11, 95% CI 0.84 to 1.47), hypertension (HR=1.03, 95% CI 0.81 to 1.29), syncope (HR=0.94, 95% CI 0.57 to 1.55) and tachycardia (HR=1.08, 95% CI 0.48, 2.41). There was a decrease in the tiotropium group in the rate of heart failure (HR=0.85, 95% CI 0.63 to 1.14) and all-cause mortality (HR=0.70, 95% CI 0.56 to 0.89).

###### 

Incidence rates and adjusted rate ratio estimates in new users of long-acting bronchodilators

  Adverse events                       Tiotropium, n=4767   LABA,[\*](#table-fn4){ref-type="table-fn"} n=6073   Crude   Adjusted                                
  ------------------------------------ -------------------- --------------------------------------------------- ------- ---------- ------ ------- ------ ------ --------------
  Death (any)                          152                  2775                                                5.48    170        2303   7.38    0.74   0.70   0.56 to 0.89
  Cardiovascular                                                                                                                                                
   Aneurysm                            17                   2765                                                0.61    13         2298   0.57    1.09   0.96   0.44 to 2.05
   Atrial fibrillation/flutter         87                   2725                                                3.19    76         2272   3.34    0.95   0.99   0.71 to 1.38
   Cardiac arrest                      3                    2774                                                0.11    4          2303   0.17    0.65   ─      ─
   Coronary artery disease             125                  2712                                                4.61    102        2255   4.52    1.02   1.11   0.84 to 1.47
   Angina                              53                   2746                                                1.93    38         2275   1.67    1.16   1.38   0.88 to 2.16
   Myocardial infarction               35                   2765                                                1.27    23         2297   1.00    1.26   1.26   0.72 to 2.21
   Heart failure                       93                   2738                                                3.40    105        2265   4.64    0.73   0.85   0.63 to 1.14
   Hypertension                        169                  2654                                                6.37    163        2232   7.30    0.87   1.03   0.81 to 1.29
   Stroke                              45                   2750                                                1.64    28         2296   1.22    1.34   1.49   0.91 to 2.45
   Syncope                             35                   2762                                                1.27    35         2289   1.53    0.83   0.94   0.57 to 1.55
   Tachycardia                         15                   2769                                                0.54    11         2296   0.48    1.13   1.08   0.48 to 2.41
   Ventricular tachycardia             2                    2774                                                0.07    1          2302   0.04    1.66   ─      ─
  Respiratory                                                                                                                                                   
   Asthma exacerbation                 98                   2716                                                3.61    395        2140   18.46   0.20   0.46   0.36 to 0.57
   COPD exacerbation                   287                  2637                                                10.88   313        2168   14.44   0.75   0.95   0.80 to 1.12
   Pneumonia                           35                   2757                                                1.27    34         2297   1.48    0.86   0.96   0.58 to 1.58
  Other                                                                                                                                                         
   Constipation                        137                  2708                                                5.06    124        2251   5.51    0.92   0.95   0.74 to 1.23
   Dry mouth                           26                   2762                                                0.94    7          2299   0.30    3.09   3.66   1.52 to 8.78
   Dysphagia                           39                   2757                                                1.41    32         2292   1.40    1.01   1.02   0.62 to 1.69
   Paralytic ileus/bowel obstruction   4                    2775                                                0.14    7          2301   0.30    0.47   ─      ─
   Renal failure                       34                   2760                                                1.23    19         2295   0.83    1.49   1.40   0.77 to 2.55
   Urinary retention                   29                   2765                                                1.05    25         2290   1.09    0.96   0.97   0.55 to 1.70
   Tremor                              16                   2769                                                0.58    23         2292   1.00    0.58   0.62   0.31 to 1.22

Single-ingredient formulations.

Rate per 100 person-years.

'─' signifies the adjusted results are not presented as there are \<5 events in either tiotropium or LABA users.

COPD, chronic obstructive pulmonary disease; LABA, long-acting β-agonists; N, number of patients; Pyrs, person-years at risk; RR, rate ratio; HR, relative hazard estimated using Cox\' proportional hazards model adjusted for propensity score.

With regard to respiratory events, there was a lower rate of asthma exacerbation in patients using tiotropium compared with patients using a LABA (HR=0.46, 95% CI 0.36 to 0.57). There were similar rates of COPD exacerbations (HR=0.95, 95% CI 0.80 to 1.12) and pneumonia (HR=0.96, 95% CI 0.58 to 1.58).

Dry mouth was recorded at a higher rate in patients using tiotropium compared with patients using a LABA (HR=3.66, 95% CI 1.52 to 8.78). The rate of constipation (HR=0.95, 95% CI 0.74 to 1.23), dysphagia (HR=1.02, 95% CI 0.62 to 1.69) and urinary retention (HR=0.97, 95% CI 0.55 to 1.70) was similar in both treatment groups. There was a higher rate of renal failure in tiotropium patients (HR=1.40, 95% CI 0.77 to 2.55) and a lower rate of tremor (HR=0.62, 95% CI 0.31 to 1.22).

Among patients who had been receiving long-acting bronchodilator therapy for at least 6 months, effect estimates increased for stroke (HR=1.63, 95% CI 0.83 to 3.17), angina (HR=1.42, 95% CI 0.78 to 2.59) and MI (HR=1.65, 95% CI 0.63 to 4.27). The difference between groups in rates of total mortality diminished (HR=0.90, 95% CI 0.58 to 1.38). Associations for other cardiovascular events were weaker, including aneurysm (HR=0.82, 95% CI 0.27 to 2.45), atrial fibrillation/flutter (HR=1.17, 95% CI 0.70 to 1.94), heart failure (HR=0.77, 95% CI 0.47 to 1.24), hypertension (HR=1.07, 95% CI 0.79 to 1.45), syncope (HR=0.79, 95% CI 0.36 to 1.70) and tachycardia (HR=0.98, 95% CI 0.32 to 3.04).

Effect estimates for respiratory end points among patients treated for at least 6 months were similar to those in the total population (asthma exacerbation (HR=0.47, 95% CI 0.33 to 0.65), COPD exacerbation (HR=0.82, 95% CI 0.63 to 1.05) and pneumonia (HR=1.42, 95% CI 0.68 to 2.96)). Effect estimates computed for other events included constipation (HR=0.97, 95% CI 0.69 to 1.37), dysphagia (HR=1.30, 95% CI 0.65 to 2.58), renal failure (HR=1.17, 95% CI 0.51 to 2.66), urinary retention (HR=1.17, 95% CI 0.51 to 2.66) and tremor (HR=0.57, 95% CI 0.23 to 1.41).

After stratifying by subgroups, results were imprecise and generally similar to the overall results. With regard to concomitant asthma diagnosis, the association with angina was stronger in patients with asthma and COPD (HR=1.91, 95% CI 1.00 to 3.63) than patients with only COPD (HR=0.93, 95% CI 0.49 to 1.77), while the association with MI was stronger in patients who had only COPD (HR=1.94, 95% CI 0.77 to 4.94). Asthma exacerbations occurred only among patients with a concomitant diagnosis of asthma. After stratification by coronary artery disease, the association with angina was stronger among patients without coronary artery disease (HR=3.02, 95% CI 1.08 to 8.47) than among patients with coronary artery disease (HR=1.05, 95% CI 0.63 to 1.77). After stratification by corticosteroids, the association with angina was greater among patients without corticosteroids (HR=2.28, 95% CI 0.99 to 5.26) than with corticosteroids (HR=1.09, 95% CI 0.63, 1.89), while the association with stroke was greater for patients with corticosteroids (HR=1.85, 95% CI 1.00 to 3.44) than without corticosteroids (HR=0.86, 95% CI 0.37 to 2.01).

Discussion
==========

This study found small increased risks of stroke, MI and angina along with a decreased risk of mortality with tiotropium. Individual studies are often too small to identify with certainty associations between specific medications and rare adverse events, and these findings should be considered in context with other evidence.

In 2002, the Lung Health Study, the first large placebo-controlled randomised trial of an inhaled anticholinergic agent reported an increased incidence in the ipratropium group of hospitalisation due to SVT, angina, MI and death due to coronary heart disease.[@b18] Observational studies have reported associations between ipratropium and stroke,[@b19] cardiovascular hospitalisation[@b20] and death.[@b21]

Tiotropium has a similar mechanism of action to ipratropium, and in 2008, the FDA issued an early communication after a pooled analysis of placebo-controlled clinical trials revealed an excess risk of stroke with tiotropium.[@b22] Subsequently, the Uplift trial reported a decreased risk of total mortality, MI and no increased risk of stroke with tiotropium.[@b23] As in other studies, the stroke end point was a composite end point that included ischaemic and hemorrhagic stroke,[@b23] and the incidence of ischaemic stroke in the Uplift study was slightly greater in the tiotropium group than the placebo group.[@b24] [@b25] In addition, the Uplift study showed an increased risk with tiotropium of certain tachyarrhythmias[@b26] and serious angina.[@b23]

A pooled analysis of randomised trials reported an increased rate of arrhythmias with tiotropium compared with placebo or LABAs and increased risks with tiotropium of both cardiovascular and cerebrovascular serious adverse events (RR=1.71, 95% CI 0.76 to 3.89).[@b27] A randomised trial comparing tiotropium with salmeterol in combination with fluticasone reported increased cardiac adverse events with tiotropium.[@b28] An observational study reported increased risk of mortality with tiotropium compared with LABA.[@b29] Pooled analyses of placebo-controlled tiotropium clinical trials have reported small increased rates with tiotropium of palpitations, SVT, angina and stroke and lower rates of MI, cardiovascular mortality and total mortality.[@b30; @b31; @b32]

Perhaps the most relevant study is the recent 'POET' study, the largest tiotropium randomised trial conducted to date, with 7376 COPD patients.[@b33] The POET Study is similar to this study in that, it compared tiotropium HandiHaler with salmeterol. The POET Study also found fewer deaths for tiotropium (n=64) compared with salmeterol (n=78), although there was no decrease in cardiac deaths (eight tioptropium vs six salmeterol)[@b33] (supplementary appendix). The POET Study reported no increased risk of stroke but found an increased risk with tiotropium of several serious cardiovascular adverse events including angina (nine tiotropium vs five salmeterol), myocardial ischaemia (11 tiotropium vs six salmeterol) and MI (20 tiotropium vs 13 salmeterol).[@b33] [@b34]

Recently, safety concerns have been raised about increased mortality with the mist inhaler formulation of tiotropium (Respimat®), which is available in several countries but which was not approved for marketing in the USA.[@b35] (Tiotropium Respimat was not available in the UK at the time of this analysis.) It was hypothesised that the increased risk of deaths, which were mostly cardiac and sudden or unexplained deaths, may be the result of the device delivering a greater dose than the powder formulation.[@b36] Tiotropium Respimat is also associated with a dose-related increased risk of angina and cardiac ischaemic events, but not MI.[@b37] [@b38]

The decreased risk of mortality observed in this study with tiotropium is in agreement with the results reported in the Uplift[@b23] and POET[@b33] studies, but not in the ipratropium Lung Health Study[@b18] or several large tiotropium trials using the Respimat device.[@b37] [@b39] These drugs have virtually identical safety profiles,[@b2] [@b3] [@b40] so it would be an oversimplification to suggest that they have either beneficial or harmful effects on mortality based solely on the device delivering similar active ingredients. Heterogeneity of results should be considered in light of both causal and non-causal explanations. For composite end points, interpretation often can be clarified by evaluating components, especially cardiovascular deaths. Thus, the POET Study reports fewer total deaths with tiotropium[@b33] but more cardiac deaths.[@b34]

The results for angina, MI and stroke reported here and in other studies of inhaled anticholinergic drugs are usually not statistically significant. The absence of statistical significance in studies that lack the power to detect small effects should be expected and does not indicate the absence of an effect.[@b41] [@b42] For instance, repeated findings of an increased risk of angina of a similar magnitude in studies of different design and locations make chance an unlikely explanation for this finding.

Non-randomized studies must always be concerned with possible bias arising from differences in baseline risks between treatment groups. We used propensity scores and multivariate models to control efficiently for available risk factors. Nevertheless, certain variables, such as lung function results, were unavailable and could not be controlled. We found that more LABA patients than tiotropium patients had an asthma diagnosis in addition to their COPD diagnosis. The decreased risk of asthma exacerbations in the tiotropium group is consistent with a greater proportion of patients in the LABA group having an asthma component to their COPD. Nevertheless, COPD diagnoses and exacerbations were similar between groups, suggesting similar severity of COPD. Nevertheless, it is possible that tiotropium patients had more severe COPD than LABA patients despite our efforts to control for baseline risk factors. More severe COPD might account for higher rates of cardiovascular events, although the decreased mortality in the tiotropium group is inconsistent with this hypothesis. Increased risks of ischaemic cardiovascular events in randomised trials also argue against confounding as an explanation.

All tiotropium effect estimates in this study are relative to effects of LABA. A valid effect estimate indicating a higher rate with tiotropium means that tiotropium increases risk more than LABA but both drugs could be either increasing or decreasing risk. To the extent that LABA may increase the risk of cardiovascular adverse events, such an effect would attenuate an increased risk that might also exist for tiotropium.

Among non-cardiovascular and non-respiratory end points, results showed an increased risk of dry mouth with tiotropium, but not for other anticholinergic end points including constipation and urinary retention. The incidence of these less serious events was low; however, and it is likely that only a small proportion of these cases are reported to GPs and recorded in the database. Under-reporting of non-serious AEs could introduce misclassification that would dilute RR estimates for events such as dry mouth and constipation.[@b15] Misclassification could have occurred for more serious end points as well, although we would expect that completeness of the medical record would be better for more serious cardiovascular events. Misclassification of certain serious end points still is a concern, however, as we examined total mortality and total strokes, but not cardiovascular mortality or ischaemic strokes. Finally, tiotropium HandiHaler is available in one dose, and this study was unable to evaluate dose--response. However, among patients using therapy for at least 6 months, the associations with angina, MI and stroke became stronger, while the association with mortality became weaker.

Results of this study should be interpreted cautiously, but they lend modest support to a considerable body of evidence of a serious cardiovascular safety risk with inhaled anticholinergic drugs. Nevertheless, with regard to safety of inhaled anticholinergic drugs, the FDA recently concluded that 'data from Uplift adequately addressed the potential safety signal of stroke and adverse cardiovascular outcomes.'[@b43] A few points help explain these divergent conclusions. First, we consider the entire body of evidence pertaining to class effects, and we consider each study on its merits. In particular, studies should not be disregarded merely because they are not randomised[@b19; @b20; @b21] [@b29] or they include an another medication as a control group instead of a placebo group.[@b28] [@b33] Second, when considering the evidence pertaining to small effects on rare adverse events, we do not assume that results that are not statistically significant provide evidence against an increased risk.[@b41] [@b42] This is especially important when increases in risk are small or studies were not large enough to detect such risks as statistically significant. It is important to consider the magnitude of effect estimates and the precision with which they are measured.[@b41] [@b42] The Uplift study, for instance, describes higher rates of serious angina and ischaemic stroke with tiotropium than placebo[@b24] and so can hardly provide reassurance about the absence of such risks. In addition, results from composite end points do not necessarily apply to each of their components. Thus, decreased rates of total mortality and total stroke can mask increased rates of cardiovascular mortality[@b24] or ischaemic stroke.[@b34] Finally, adverse effects do not occur in every patient and may not be apparent in every population or every study. Heterogeneity of results is not evidence against a causal effect but is an interesting finding that should be interpreted in consideration of the impact of both non-causal as well as causal explanations; the latter include differences in populations, durations of follow-up and doses. Thus, the absence of an increased risk of MI in the Uplift study does not negate increases in risk of MI in the Lung Health Study,[@b18] POET Study[@b34] or this study, especially when each of these studies indicates an increased risk of angina.

Inhaled anticholinergic drugs are effective treatments in COPD and treatment decisions must balance benefits with risks for individual patients. It has long been suggested that older people are especially susceptible to anticholinergic effects, and angina has been described previously as a severe anticholinergic effect secondary to tachyarrhythmias.[@b1] [@b4] [@b5] Subsequently, increased risks of tachyarrhythmias and angina have been reported in association with inhaled anticholinergic drugs in non-randomised and randomised studies, of various sizes and durations, with ipratropium and tiotropium, compared with placebo and active comparators, and using different devices. Pharmacological and clinical evidence, therefore, supports these cardiovascular events as class effects of inhaled anticholinergic drugs. Small increased rates of stroke have been observed fairly consistently across studies, while MI, and cardiovascular death, have been associated in different studies both positively and negatively with anticholinergic medication. Additional research is needed to understand the full extent of cardiovascular effects of inhaled anticholinergic medications and the patients who may be susceptible.
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